RhumbLine Advisers
TNGX icon

RhumbLine Advisers’s Tango Therapeutics TNGX Stock Holding History

RhumbLine Advisers’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.47M Buy
175,133
+48,530
+38% +$1.2M ﹤0.01% 1425
2026
Q1 		$2.65M Sell
126,603
-2,504
-2% -$34.9K ﹤0.01% 1717
2025
Q4 		$1.14M Buy
129,107
+21,268
+20% +$183K ﹤0.01% 2155
2025
Q3 		$906K Sell
107,839
-4,434
-4% -$30K ﹤0.01% 2306
2025
Q2 		$575K Buy
112,273
+45,467
+68% +$112K ﹤0.01% 2598
2025
Q1 		$91.5K Buy
66,806
+1,066
+2% +$2.62K ﹤0.01% 3416
2024
Q4 		$203K Buy
65,740
+1,895
+3% +$8.8K ﹤0.01% 3193
2024
Q3 		$492K Sell
63,845
-3,495
-5% -$33.4K ﹤0.01% 2705
2024
Q2 		$578K Sell
67,340
-4,097
-6% -$31.7K ﹤0.01% 2566
2024
Q1 		$567K Buy
71,437
+1,047
+1% +$11.2K ﹤0.01% 2588
2023
Q4 		$697K Buy
70,390
+624
+0.9% +$5.42K ﹤0.01% 2480
2023
Q3 		$786K Sell
69,766
-859
-1% -$5.24K ﹤0.01% 2345
2023
Q2 		$234K Sell
70,625
-1,096
-2% -$3.94K ﹤0.01% 3156
2023
Q1 		$283K Buy
71,721
+1,031
+1% +$5.98K ﹤0.01% 2633
2022
Q4 		$513K Buy
70,690
+938
+1% +$6.6K ﹤0.01% 2450
2022
Q3 		$253K Buy
69,752
+3,818
+6% +$16.3K ﹤0.01% 2807
2022
Q2 		$299K Buy
+65,934
New +$399K ﹤0.01% 2753

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

RhumbLine Advisers's TNGX Position: Q2 2026 in Review

RhumbLine Advisers increased its Tango Therapeutics (TNGX) stake by 38% in Q2 2026, buying an estimated $1.2M and bringing the position to 175,133 shares worth $5.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

RhumbLine Advisers first reported a position in TNGX in Q2 2022 and has held it in 17 quarters since. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • RhumbLine Advisers held 175,133 shares of Tango Therapeutics worth $5.47M as of Q2 2026.
  • RhumbLine Advisers bought 48,530 Tango Therapeutics shares in Q2 2026, an estimated $1.2M.
  • Tango Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1425 holding.
  • RhumbLine Advisers first reported a position in Tango Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.